Katrina Church promoted to VP, chief compliance officer at Merz
GREENSBORO, N.C. — Merz has promoted one of its executives to serve as VP and chief compliance officer.
The company said Katrina Church, who joined the company in November 2009, now will be responsible for providing strategic and operational leadership relating to compliance issues. Church officially took on the new responsibilities July 1.
"Katrina brings extensive experience and a wealth of legal knowledge in pharmaceutical regulatory compliance to her new role," Merz president and CEO Bill Humphries said. "Merz is committed to a tight set of core values that foster a positive, productive and unified work environment. As a company, we do what is right even when it is not easy. Katrina plays a vital role in ensuring that we uphold the highest standards and values in this dynamic regulatory environment. We look forward to working with her on the many compliance requirements facing pharmaceutical companies today."
Former Dendreon executive joins Onyx
SOUTH SAN FRANCISCO, Calif. — Onyx Pharmaceuticals has appointed a new SVP global corporate affairs.
John Osborn will be responsible for the public and government affairs activities of the company, as well as key stakeholder relationships, and will report to Onyx’s president and CEO N. Anthony Coles.
Prior to joining Onyx, Osborn previously served as EVP, general counsel and secretary at Dendreon.
FDA approves Lilly, BMS drug for KRAS wild-type colorectal cancer
NEW YORK — The Food and Drug Administration has approved a drug made by Eli Lilly and Bristol-Myers Squibb for treating a form of colorectal cancer, the two companies said.
Lilly and Bristol announced the approval of Erbitux (cetuximab) for treating colorectal cancer that is KRAS mutation-negative, expresses the epidermal growth factor receptor and has spread to other parts of the body, also known as metastasis. The drug is approved for use alongside a chemotherapy combination containing irinotecan, 5-fluorouracil and leucovorin, also known as FOLFIRI.
"Cancer is a heterogeneous disease, and we have learned that not all patients with mCRC should be viewed as the same," Bristol-Myers Squibb SVP global development and medical affairs Brian Daniels said. "Today’s approval demonstrates our ability to bring diverse cancer therapies to market that address the needs of patients with KRAS mutation-negative mCRC."
The drug already is approved for treating head and neck cancer.